NCT07877974 Efficacy of Gastrocnemius Plane Block for Foot and Ankle Surgery
| NCT ID | NCT07877974 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Gastrocnemius |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-11 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-11 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aim is to evaluate the efficacy of the gastrocnemius plane block (GPB) in providing postoperative analgesia for patients undergoing foot and ankle surgery. Objectives: * To evaluate the duration of postoperative analgesia provided by the gastrocnemius plane block * To assess postoperative opioid or rescue analgesic consumption within the first 24 hours after surgery * To measure postoperative pain intensity at predefined time intervals using a validated pain scale (e.g., VAS). * To assess the incidence of block-related complications, including motor weakness, vascular puncture, nerve injury, or local anesthetic systemic toxicity We hypothesize that GPB will result in lower postoperative pain scores and reduce opioid/rescue analgesic consumption compared with standard analgesic management after foot and ankle surgery.
Eligibility Criteria
Inclusion Criteria: * Elective foot and ankle surgeries, including procedures for fractures of the fibula, tibia-fibula, metatarsal, or calcaneus, as well as corrective surgery for hallux valgus; * Aged 18- 65 years * BMI 18-28 kg/m2 * ASA Ⅰ-Ⅲ. Exclusion Criteria: * Puncture site infection * Abnormal coagulation function: international normalized ratio (INR) \> 1.5; platelet count \< 50×109/L * Local anaesthesia allergy * Unstable coronary syndrome (e.g., recent myocardial infarction within 3 months); * Severe cardiopulmonary disease: heart failure (NYHA, functional class III or IV) * Severe pulmonary disease (e.g., chronic obstructive pulmonary disease with FEV1 \< 50% of predicted, or requiring home oxygen therapy) * Liver insufficiency: liver disease (Child- Pugh class B or C) or elevated liver enzymes (ALT or AST) \> 3 times the upper limit of normal; * Renal insufficiency renal impairment (estimated glomerular filtration rate, eGFR\<30 mL/min/1.73m2) or requiring renal replacement therapy * Long-term preoperative use of sedative and analgesic drugs; * Communication disorders * History of chronic pain. * Operative time \> 3 h.
Contact & Investigator
Nagy Malak, MD
PRINCIPAL INVESTIGATOR
Cairo University
Frequently Asked Questions
Who can join the NCT07877974 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Gastrocnemius. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07877974 currently recruiting?
Yes, NCT07877974 is actively recruiting participants. Contact the research team at nagymalak@kasralainy.edu.eg for enrollment information.
Where is the NCT07877974 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07877974 clinical trial?
NCT07877974 is sponsored by Cairo University. The principal investigator is Nagy Malak, MD at Cairo University. The trial plans to enroll 40 participants.